Search Tag: ER-positive breast cancer
2025 12 May
Accurate assessment of oestrogen receptor (ER) status is critical in guiding endocrine therapy for metastatic breast cancer. Biopsies are commonly used to determine ER status, yet they are susceptible to sampling errors and may not reflect the heterogeneity across lesions. Imaging alternatives such as computed tomography (CT) and 18F-fluorodeoxyglucose...Read more
2025 12 May
Accurate assessment of oestrogen receptor (ER) status is critical in guiding endocrine therapy for metastatic breast cancer. Biopsies are commonly used to determine ER status, yet they are susceptible to sampling errors and may not reflect the heterogeneity across lesions. Imaging alternatives such as computed tomography (CT) and 18F-fluorodeoxyglucose...Read more
2025 12 May
Accurate assessment of oestrogen receptor (ER) status is critical in guiding endocrine therapy for metastatic breast cancer. Biopsies are commonly used to determine ER status, yet they are susceptible to sampling errors and may not reflect the heterogeneity across lesions. Imaging alternatives such as computed tomography (CT) and 18F-fluorodeoxyglucose...Read more
2025 17 Mar
Accurate staging plays a crucial role in the management of breast cancer, as it determines treatment plans and informs prognosis. Conventional staging methods primarily utilise 18F-FDG PET, which detects metabolic activity by measuring glucose uptake in cancerous tissues. However, this approach has limitations when applied to low-grade oestrogen...Read more